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Abstract 
mTOR is a central regulator of cell growth and has been implicated in responses to 
stress such as hypoxia. We have shown before that mTOR is required for 
angiogenesis in vitro and endothelial cell proliferation in response to hypoxia. Here 
we have investigated mTOR-associated signaling components under hypoxia and 
their effects on cell proliferation in rat aortic endothelial cells (RAEC). 
Hypoxia (1% O2) rapidly (>30 min) and in a concentration-dependent manner 
promoted rapamycin-sensitive and sustained phosphorylation of mTOR-Ser2448 
followed by nuclear translocation in RAEC. Similarly, hypoxia induced 
phosphorylation of the mTORC2-substrate Akt-Ser473 (3-6 h at 1% O2) and a brief 
phosphorylation peak of the mTORC1-substrate S6K-Thr389 (10-60 min). 
Phosphorylation of Akt was inhibited by mTOR knockdown and partially with 
rapamycin. mTOR knockdown, rapamycin or Akt inhibition specifically and 
significantly inhibited proliferation of serum-starved RAEC under hypoxia (P<0.05; n 
≥ 4). Similarly, hypoxia induced Akt-dependent and rapamycin-sensitive proliferation 
in mouse embryonic fibroblasts. This response was partially blunted by HIF-1α 
knockdown and not affected by TSC2 knockout. Finally, mTORC2-inhibition by rictor 
silencing especially (P<0.001; n=7), and mTORC1-inhibition by raptor-silencing 
partially (P<0.05; n=7), inhibited hypoxia-induced RAEC proliferation.  
Thus, mTOR mediates an early response to hypoxia via mTORC1 followed by 
mTORC2 promoting endothelial proliferation mainly via Akt-signaling. mTORC1 and 
especially mTORC2 might therefore play important roles in diseases associated with 
hypoxia and altered angiogenesis.  
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INTRODUCTION 
Hypoxia is associated with angina pectoris, myocardial infarction, heart failure and 
peripheral artery disease. Hypoxia and tissue ischemia is either caused by arterial 
obstruction or functional and anatomical capillary rarefaction because of hypertension 
1
. Hypoxia occurs during rapid tissue growth, in organ and in tumor development and 
during chronic inflammation or exposure to high altitude 1. Diminished oxygen 
concentration induces programmed responses such as endothelial proliferation 2,3 
and angiogenesis which ultimately relieves tissue hypoxia and contributes to wound 
healing 4.  
We have reported that hypoxia requires mammalian target of rapamycin (mTOR) to 
induce angiogenesis and cell proliferation of the vascular wall in response to hypoxia 
5
. The mTOR pathway is a key regulator of cell growth and proliferation and 
increasing evidence suggests that its deregulation is associated with human 
diseases, including cancer, diabetes and cardiovascular disease 6. The mTOR 
pathway integrates signals from nutrients, energy status and growth factors to 
regulate many processes, including autophagy, ribosome biogenesis and metabolism 
6
. Recent work identified two structurally and functionally distinct mTOR-containing 
multiprotein complexes 7,8: The first complex, mTORC1, harbors raptor, and is highly 
rapamycin-sensitive, 9-13 and specifically activates protein synthesis via S6K. The 
second complex, mTORC2 13-15, is associated with rictor and phosphorylates Akt on 
Ser473 16,17. mTORC2 phosphorylates and activates Akt/PKB, which promotes 
signaling pathways that ensure cell survival and induce cell proliferation 18.  
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Reports on the effects of hypoxia on mTOR are contradicting; On the one hand, 
hypoxia activates mTOR-signaling to enhance angiogenesis 19, cellular proliferation 
of lung adventitial fibroblasts 20 and aortic wall cells 5, or protein levels and activity of 
HIF-1α, a major transcription factor for hypoxia-inducible genes 21. On the other 
hand, hypoxia has also been reported to inhibit mTOR signaling in mouse embryonic 
fibroblasts, which dephosphorylates S6K1 and downregulates protein synthesis 22-24. 
It is unclear, how hypoxia can elicit both activation and inhibition of mTOR signaling 
and how these signals contribute to increased proliferation; Furthermore, it is 
currently not known, whether hypoxia affects mTORC2 and mTOR-dependent Akt-
phosphorylation.  
This study further assesses the effects of hypoxia on mTOR signaling in endothelial 
cells 5. Here we examine activities of mTOR under hypoxia in detail and translation of 
this signal into endothelial cell proliferation. 
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MATERIALS AND METHODS 
Rat aortic endothelial cells (RAEC) were prepared, cultured and characterized as 
described previously 5. Tsc2 defective MEFs were obtained from Michael Hall 
(Biocenter, Basel, Switzerland), HIF-1α knockouts from Max Gassman (University of 
Zürich, Switzerland). Endothelial cell spheroids were generated as described 
elsewhere 25. Predesigned siRNAs against rat mTOR (frap1_3 siRNA) were 
purchased from Qiagen. shRNA containing vectors against raptor an rictor are 
pKDM-132, a pSuper.gfp/neo-based siRNA expressing plasmid targeting 
ctgtgaactagcacttcag in rictor mRNA; pKDM-162 is a pSuper.gfp/neo-based plasmid 
targeting ggacaacggccacaagtac in raptor mRNA. RAEC were transfected with 
si/shRNA by AMAXA nucleofection. Cell numbers were assessed using Cell 
Proliferation Reagent WST-1 (Roche Molecular Biochemicals) according to the 
manufacturer’s specifications.  
Cell lysis was prepared as described previously 5 and as described elsewhere 26. 
Primary chicken polyclonal anti-HIF-1α antibodies were provided by Max Gassmann 
(University of Zürich, Switzerland), polyclonal anti-raptor and anti-rictor antibodies 
were generated by Markus A. Rüegg (Biocenter Basel, Switzerland). All other 
antibodies are commercially available. Protein bands were analyzed by densitometric 
quantification by ImageJ 1.31v software (Wayne Rasband, NIH). Immunestaining 
was performed as described previously 27. 
Data (mean±SEM) were analyzed for normal distribution (one-way or repeated 
measures ANOVA), followed by multiple or pairwise comparison with the Bonferroni 
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post test using the Graphpad software Prism. The number of single experiments 
compiled is indicated by n. A value of P<0.05 was considered as significant. 
 
RESULTS 
Hypoxia rapidly and concentration-dependently promotes phosphorylation of 
mTOR-Ser 2448 and mTOR nuclear translocation  
To investigate direct effects of hypoxia on mTOR activity we have performed time-
course experiments in serum-deprived cultured aortic endothelial cells, in the 
absence of growth factors. We determined phosphorylation of mTOR at Ser2448 and 
Ser2481 in the presence and absence of rapamycin. As shown in figure 1A, 
phosphorylation of Ser2448 rapidly increases after exposure to hypoxia (1% O2), 
peaks at around 3h of hypoxia and remains at high levels during the period 
investigated (24 h). The effect of hypoxia on Ser2448 phosphorylation is reduced by 
rapamycin (Fig. 1A). In contrast, phosphorylation of mTOR Ser2481 increased only 
slightly during hypoxic exposure and declined towards 24h of incubation. mTOR 
protein levels were not affected by hypoxia (Fig 1A). 
In mammalian organs, O2 concentration ranges from 14% to 0.5%, with 14% O2 in 
arterial blood and 10% in the myocardium. During mild hypoxia, myocardial O2 drops 
to 1% to 3% or lower 28. To account for varying oxygen concentrations in the body, 
we investigated the effect of different oxygen saturations on mTOR Ser2448 
phosphorylation. Quiescent RAEC were separately incubated under decreasing 
oxygen saturations (20%, 11%, 6%, 3% and 1% O2) for 12 h. At normoxia (21% O2), 
faint phosphorylation of mTOR Ser2448 was detected, which increased when O2 
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concentration was lowered to 11 – 6% and augmented further with a maximum at 1-
3% O2 (Fig.1B). mTOR protein- as well as β-actin protein levels were not affected by 
oxygen saturation. HIF-1α protein levels were used as a positive control for hypoxia 
and increased linearly peaking at 1-3% of O2 saturation (Fig. 1B). Thus, mTOR 
phosphorylation on Ser2448 is modulated in the pathophysiologic O2 concentration 
range.  
An additional regulatory mechanism of mTOR signaling may occur via cytoplasmic-
nuclear shuttling 29. We examined whether severe hypoxia (1% O2) influences 
cellular localization of mTOR and mTOR P-Ser2448. Under all tested conditions, 
mTOR was localized predominantly in the cytosol as shown by immunostaining in 
Fig. 1C. However, after quiescent RAEC were cultured in hypoxia for 6 h, mTOR 
protein also appeared in the nucleus, and rapamycin treatment inhibited nuclear 
localization (Fig. 1C). Interestingly, mTOR-P-Ser2448 was only detected in distinct 
nuclear structures after 6 h of exposure to hypoxia. Phosphorylation of mTOR Ser2448 
was not detected under normoxia and only a very faint signal was detected under 
conditions of hypoxia with rapamycin treatment (Fig. 1C). Similar results were 
obtained when assessing protein levels of mTOR and mTOR P-Ser2448 by Western 
blotting. Serum-deprived RAEC were exposed to hypoxia (1% O2) for different 
periods of time (2 – 24 h). At normoxia (Time point = 0) basal levels of HIF-1α were 
detected in nuclear extracts, whereas the levels of mTOR and mTOR-P-Ser2448 were 
nearly undetectable (Fig. 1D). mTOR and mTOR-P-Ser2448 protein levels appeared in 
the endothelial nuclear fraction after 2 h of incubation under 1% O2, increased slightly 
with time and were maximal after 24 h of incubation under 1% O2 (Fig. 1D). Thus, 
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hypoxia rapidly and dose-dependently promotes phosphorylation of mTOR-Ser2448 in 
a rapamycin-sensitive way and causes nuclear translocation of phosphorylated 
mTOR. 
Hypoxia induces rapid, but short-term mTOR–dependent phosphorylation of 
S6K1-Thr389 and sustained phosphorylation of Akt-Ser473  
mTOR is present in two complexes, mTORC1 and mTORC2. mTORC1 activity can 
be measured by analyzing the phosphorylation of the direct downstream target S6K1 
on Thr389 or phosphorylation of ribosomal subunit S6 30,31. mTORC2 phosphorylates 
Akt on the primary phosphorylation site Ser473 16,17. We therefore performed time 
course experiments, where quiescent RAEC were exposed to hypoxia (1% O2) for 
short (10 min) to long (24 h) term and we analyzed phosphorylation of S6K1-Thr389 
and Akt-Ser374 phosphorylation. As shown representatively in figure 2A (first three 
panels) and as averaged densitometric quantification of cumulative experiments in 
Fig. 2B, upper graph, S6K1 was highly phosphorylated at Thr389 between 10 min to 1 
h of hypoxic exposure but dropped to undetectable levels after more than 3 h of 
culture under hypoxia. This phosphorylation step is highly rapamycin-sensitive. Akt 
phosphorylation at Ser473 slightly increased after 10 min, but reached maximal levels 
after 3 h of hypoxic exposure before staying at a steady level for up to 24 h. Total Akt 
levels remained unchanged under hypoxia (Fig 2A, middle four panels). 
Phosphorylation of Akt at Ser473 peaked after 3 h of exposure to hypoxia as shown in 
Figure 2B, lower graph, representing the ratio of Akt-P-Ser473 to total Akt. Akt 
phosphorylation was partially inhibited by rapamycin, however, rapamycin’s effect 
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increased with longer incubation (averaged densitometric quantification of cumulative 
experiments in Fig. 2B, lower graph).  
Akt phosphorylates Ser21 in Glycogen synthase kinase-3 (GSK3) α and Ser9 in 
GSK3β and thereby inactivates GSK3 function 32,33. Furthermore Akt and GSK3 are 
implicated in the regulation of cell cycle regulators Cyclin D1 and p2133. Similar to Akt 
phosphorylation, GSK3β was phosphorylated after 60 min of exposure to hypoxia as 
shown by westernblots of nuclear extracts in Fig. 2A. Cyclin D1 protein gradually 
accumulated after 30 min of hypoxia in the nuclear fraction, whereas cell cycle 
inhibitor p21 protein levels decrease and totally disappear after 24 h of RAEC 
cultivation under hypoxia (Fig 2B). 
To further examine the role of mTOR on Akt-P-Ser473 under hypoxia, mTOR protein 
expression was silenced by mTOR specific siRNAs that were nucleo-fected into 
RAEC prior to starvation and exposure to hypoxia. Quiescent RAEC were then again 
exposed to hypoxia (1% O2) for short (10 min) to long (24 h) term and Akt-Ser374 
phosphorylation was analyzed by Western blotting. mTOR silencing as shown by the 
Western blots in Figure 2C and averaged densitometric quantification of cumulative 
data in Fig. 2D effectively blunted hypoxia-induced Akt-Ser374 phosphorylation. 
Thus, hypoxia induces sustained phosphorylation of Akt-Ser473, peaking at around 3-
6 h of hypoxia that is blunted by rapamycin or mTOR silencing. On the other hand, 
rapamycin sensitive S6K1 phosphorylation on Thr389 peaks between 10 min to 1 h of 
exposure to hypoxia, but quickly drops to undetectable levels with further culture 
under hypoxia. 
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Hypoxia-enhanced endothelial proliferation is mTORC1- and mTORC2-
dependent 
We compared our previous findings 5 in rat aortic angiogenesis with an angiogenesis 
assay of endothelial spheroids and endothelial proliferation assays using RAEC at 
severe hypoxia (1% O2). Endothelial sprout-formation under 1% O2 was more than 
twice as high when compared to the response under 21% O2 (Fig. 3A). Rapamycin 
selectively inhibited additional sprout-formation observed under 1% O2 at a low 
concentration (2 nM) (Fig. 3A). We have shown previously that hypoxia-enhanced 
angiogenesis in vitro is mainly due to enhanced proliferation 5. A similar response 
was observed for RAEC proliferation under 1% O2; Hypoxia alone increased RAEC 
proliferation when compared to diluent normoxic control to about 1.5 fold (Fig. 3B). 
Low concentrations of rapamycin (2 nM) inhibited proliferation specifically under 
hypoxia (Fig. 3B, upper graph). Akt inhibition by Akt IV inhibitor lowered overall 
proliferation at higher concentrations (Fig. 3B, lower graph). Akt inhibitor was used 
within concentrations where cytotoxicity was absent, as shown by cytotoxicity test 
performed in RAEC (see supplemental figure). 
To further assess the role of mTOR in transducing hypoxia into endothelial 
proliferation, we analyzed endothelial (RAEC) proliferation and mTOR–associated 
signaling after mTOR silencing. mTOR protein was consistently knocked down or 
reduced (up to 95%) by mTOR siRNA, whereas control siRNA had no effect on 
mTOR protein as shown by Western blotting (Figure 2C). After silencing, quiescent 
endothelial cells were cultured for 30 h under 1% O2 and 21 % O2 and proliferation 
was measured. mTOR silencing significantly (P<0.05, n=4) decreased increased 
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proliferation under hypoxia compared to transfection with control si-RNA, whereas 
mTOR silencing had no significant (P>0.05, n=4) effects on proliferation under 
normoxia when compared to proliferation in endothelial cells that were transfected 
with control si-RNA (Fig. 3C).  
To assess whether a specific mTOR complex is responsible for transducing hypoxia 
into endothelial proliferation, we knocked down raptor, specific for mTORC1, or rictor, 
specific for mTORC2 14 by nucleofection of RAEC with vectors containing specific 
shRNAs. As shown in the upper part of Figure 3D, shRNA silencing effectively 
inhibited expression of raptor or rictor proteins as compared to negative control 
transfection. Rictor but not raptor silencing also clearly decreased phosphorylation of 
mTORC2 downstream substrate Akt-Ser473 after 6 h of incubation under hypoxia (Fig. 
3D). At these timepoints, S6K1 phosphorylation at Thr389 is repressed (Fig. 3D). 
Importantly, inhibition of mTORC2 by rictor silencing effectively blunted hypoxia-
induced endothelial proliferation with no effect on proliferation under normoxia 
(P<0.001, n=5). Also raptor-silencing decreased hypoxia-induced proliferation 
significantly (P<0.05, n=3), however, not to the extent of rictor silencing. Thus, both 
mTORC1 and especially mTORC2 silencing significantly reduces hypoxia-induced 
endothelial proliferation. 
 
Tsc2 knockout does not blunt hypoxia-induced proliferation in mouse 
embryonic fibroblasts 
In order to extend the validity of our data to other cell types that are commonly used 
in molecular biology research we have assessed MEF cells for their proliferative 
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response under hypoxia. The broad availability of transgene MEFs allows for rapid 
and easy determination of the role of a specific gene. 
Tsc2 has been implicated to regulate proliferation under hypoxia in mouse embryonic 
fibroblasts (MEFs) 24. Tsc1 and Tsc2 proteins form a physical and functional complex 
in vivo and inhibit mTOR. Tsc2 is inactivated by Akt-dependent phosphorylation or 
nutrient availability, which destabilizes Tsc2 and disrupts its interaction with Tsc1 
34,35
. We therefore investigated whether a disrupted Tsc1/Tsc2 complex in Tsc2-
defective MEFs affects hypoxia-induced cell proliferation when compared to wildtype 
MEFs or Tsc2 mutated MEFs with a reintroduced Tsc2 wild-type gene. As shown in 
Fig. 4A, proliferation was clearly increased in TSC2-/- MEFs (upper panel), both under 
normoxia and hypoxia. Hypoxia-induced proliferation was decreased by rapamycin 
and the Akt inhibitor as demonstrated for endothelial cells (Fig. 4A, upper panel). 
Importantly, proliferation in TSC2 defective MEFs was enhanced under hypoxia to a 
ratio comparable to intact MEFs. No significant decrease (P>0.05, n=3) was 
observed when comparing the ratio of proliferation indices under hypoxia to that 
under normoxia (Fig. 4A, lower graphs). These results suggest, that loss of Tsc2 
generally increases proliferation but does not regulate the specific activating effects 
of hypoxia on mTOR-mediated proliferation in MEFs. 
 
mTOR induces HIF-1α-dependent and -independent ways to promote mouse 
embryonic fibroblast proliferation under hypoxia 
mTOR was shown to contribute to the stabilization of HIF-1α protein in cells exposed 
to hypoxia and is thus a positive regulator of HIF-1-dependent gene transcription, 
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21,36,37
. We therefore asked whether HIF-1α, downstream of mTOR, is pivotal for 
increased cell proliferation under hypoxia. For this purpose we measured proliferation 
of wild-type MEFs and those lacking the HIF-1α gene. As shown in figure 4B, 
hypoxia-induced proliferation was only partially, though significantly (P>0.05, n=5) 
inhibited in HIF-1α-/- cells (open squares) as compared to wild-type cells under 
hypoxia (open circles). Both wildtype (filled circles) and HIF-1α-/- cells (filled squares) 
did not increase proliferation under normoxia. Increased proliferation under hypoxia 
was rapamycin-sensitive both in HIF-1α-/- cells and wildtype MEFs. To further assess, 
whether mTOR requires HIF-1α to induce proliferation under hypoxia, we 
overexpressed mTOR in wildtype and HIF-1α-/- cells (Fig 4C, upper panel) and 
measured proliferation (Fig 4C, lower left panel). mTOR overexpression increased 
overall proliferation in all conditions to approximately the same levels when compared 
to corresponding mock-transfected cells; the ratios (Fig 4C, lower right panel) 
between proliferation under hypoxia and under normoxia was the same in wildtype 
and in HIF-1α knockout MEFs. These results suggest, that HIF-1α is a partial but not 
crucial effector of mTOR-dependent hypoxia-induced proliferation in MEFs.  
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DISCUSSION 
In this report we have investigated the mechanisms responsible for hypoxia-induced 
proliferation of serum- and growth factor deprived endothelial cells and found that 
mTORC1 and mTORC2, i.e. the large multidomain kinase mTOR and its regulatory 
associated proteins raptor and rictor, mediate an early response to hypoxia 
promoting endothelial proliferation via Akt-signaling. Our results also clarify the 
apparent contradiction in the mTOR-field arising from earlier observations, that 
hypoxia activates mTOR signaling 38 resulting in angiogenesis 19, proliferation 5,20 and 
HIF-1α stabilization 21 and at the same time appears to inhibit mTOR signaling as 
seen by deactivation of mTORC1 substrate S6K1, 4E-BP1 and protein synthesis 22-
24; Our data suggest that both mTORC1 and mTORC2 participate in the response to 
hypoxia in a cooperative and timed program, that allows an early activation and late 
inhibition of mTORC1 and delayed and maintained activation of mTORC2.  
We demonstrate that hypoxia (1% O2) induces phosphorylation of mTORC2 
downstream target Akt-Ser473 (3-6 h) and a short phosphorylation peak at mTORC1 
substrate S6K-Thr389 (10-60 min). Thus, hypoxia activates mTOR, S6K1 and Akt in 
different ways. mTORC1-signaling appears to be activated only at a very early stage 
and is inhibited with prolonged (>3h) exposure to hypoxia, In contrast, mTORC2-
signaling is maintained; Akt-Ser473-phosphorylation increased under hypoxia at more 
than 3h and was sustained in 1% O2. Importantly, phosphorylation of Akt was 
partially inhibited by rapamycin and strongly by mTOR silencing. It has initially been 
reported that mTORC2, i.e., the rictor-mTOR complex, is rapamycin-insensitive 14,15. 
However, later studies have shown, that prolonged rapamycin treatment inhibits 
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mTORC2 assembly and in consequence, Akt/PKB in certain cell types including 
endothelial cells (HUVECs, in particular) 39. 
In line with these phosphorylation studies, mTOR silencing, rapamycin and Akt 
inhibition all specifically and significantly inhibited proliferation of serum-starved 
RAEC under hypoxia, and rapamycin also decreased endothelial sprout-formation in 
endothelial spheroids under hypoxia alone. Finally, rictor knockdown, and therefore 
inhibition of mTORC2 signaling, clearly decreased hypoxia-induced phosphorylation 
on Akt Ser473 and totally blunted hypoxia-induced endothelial proliferation. On the 
other hand, raptor silencing, and therefore inhibition of mTORC1, did not affect Akt 
phosphorylation and partially though significantly reduced hypoxia-induced 
endothelial proliferation.  
The differences of hypoxic activation of mTOR1 and mTORC2 hypothetically may 
involve distinct effects of hypoxia-induced, phosphorylation of mTOR at Ser2448: We 
show that hypoxia rapidly (10 min) and concentration-dependent promotes 
rapamycin-sensitive and sustained phosphorylation of mTOR-Ser2448 and mTOR 
nuclear translocation in RAEC. Phosphorylation of mTOR-Ser2448 was modulated in 
the physiologic oxygen saturation range (1-11% O2) also covering moderate hypoxic 
conditions. This is consistent with other responses to hypoxia to prevent or delay the 
onset of more severe hypoxia 40. However, the functional significance of the mTOR 
phosphorylation site in Ser2448 is still unknown. Phosphorylation of this site has been 
suggested to be part of a feedback mechanism regulating mTOR activity 41. Though, 
it is still unclear, whether this feedback loop is positive or negative and whether it 
affects mTORC1 or mTORC2 to the same extent 7,41. Further investigations 
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assessing whether hypoxia-induced nuclear mTOR-Ser2448 phosphorylation is 
associated with a specific mTOR- complex or -function will therefore be necessary. 
As shown by immuno-fluorescence mTOR-Ser2448 phosphorylation is localized to 
subnuclear macromolecular structures resembling promyelocytic leukaemia (PML)-
nuclear bodies. These PML-bodies represent distinct yet dynamic intra-nuclear 
structures involved in apoptosis, proliferation and senescence, and also associate 
with nuclear phosphorylated Akt 42. Indeed, very recently, PML was shown to be a 
novel suppressor of mTOR and neoangiogenesis during ischemia 19. 
Hypoxia also induces proliferation in lung adventitial- 20, cardiac- 28 and mouse 
embryonic (MEF)-24 fibroblasts. In order to extend the validity of our data to other cell 
types, we have assessed how MEF cells increase proliferation under hypoxia. In 
MEFs, a loss of Tsc2 confers a growth advantage to hypoxic cells 24, suggesting that 
hypoxia inhibits mTOR via the tuberous sclerosis complex (TSC). TSC, consisting of 
Tsc1 and Tsc2, is the main upstream inhibitor of mTOR activity. The disruption of the 
complex by Tsc2 phosphorylation results in mTOR activation 38. Indeed, we confirm 
that disrupting the Tsc2 gene increases proliferation under hypoxia. However, the 
same advantage is present in wildtype MEFs or Tsc2-mutated MEFs with a 
reintroduced Tsc2-wildtype gene. Increased proliferation to hypoxia, however, was 
specifically decreased by rapamycin and Akt-inhibitor. Based on these experiments 
we conclude that mTOR mediates hypoxia-induced cell proliferation independent of 
regulation by TSC. An autonomous role of mTOR, in sensing and transducing 
oxygen saturation was suggested by recent work revealing that a redox-sensitive 
switch may contribute to the regulatory mechanism that controls the mTOR pathway 
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43,44
. Furthermore, oxidative capacity as displayed by mitochondrial activity was 
shown to regulate mTORC1 assembly 45.  
The proliferation studies in HIF-1α knockout MEFs suggest that HIF-1α is a partial 
downstream effector of mTOR-dependent proliferation under hypoxia. However, 
mTOR can promote hypoxia-induced proliferation also in the absence of HIF-
1α ssion of mTOR in HIF-1α knockout MEFs. Still, 
further studies will have to assess the role of HIF-1α in mTOR-dependent 
proliferation in endothelial cells 46, as well as the contribution of mTORC1 and 
mTORC2 complexes to HIF-1α stability but also to the activity of cell cycle regulators 
such as Cyclin D1 and p21. 
In conclusion (see Fig. 5) hypoxia-induced proliferation in endothelial cells requires 
signaling from both mTOR complexes, mTORC1 and mTORC2. mTOR activation by 
hypoxia is monitored by an early and sustained rapamycin-sensitive phosphorylation 
and nuclear translocation of mTOR, specifically phosphorylated at Ser2448. Activation 
of mTORC2 is monitored by a sustained phosphorylation of AktSer473, which is 
decreased by mTOR and mTORC2 silencing and partially by prolonged rapamycin 
treatment. On the other hand, mTORC1 (rapamycin)-dependent S6K1 
phosphorylation at early timepoints (<3h) is likely involved in the early events that 
lead to hypoxia-mediated endothelial proliferation, whereas at later time-points (>3h) 
mTORC1 signaling is repressed as seen by complete de-phosphorylation of S6K-
Thr389. Blunting of hypoxia-induced endothelial proliferation by siRNA-mediated 
knockdown of raptor or rictor, monitors the importance of mTORC1 and especially 
TORC2, respectively. This indicates cooperating mechanisms between signals from 
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both mTOR complexes in the response to hypoxia in endothelial cells. Thus, 
mTORC1 and specifically mTORC2 may be interesting novel targets to regulate 
hypoxia-induced endothelial cell proliferation and angiogenesis for inhibition of tumor 
vascularization and potential induction of reparative angiogenesis during ischemic 
cardiovascular disease. 
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LEGENDS 
Figure 1. Hypoxia (1% O2) mediates rapid, dose-dependent, sustained 
phosphorylation of mTOR Ser 2448 and translocation to the nucleus in RAEC.  
A) Westernblot (upper panel) showing total cell lysates of serum-deprived rat aortic 
endothelial cells (RAEC) exposed to increasing duration of hypoxia (10 min to 24 h) 
and probed for phosphorylated Ser2448, phosphorylated Ser2481 and total mTOR in the 
presence or absence of rapamycin (20 nM). Averaged densitometric quantification 
(lower panel) shows rapid, sustained and rapamycin-sensitive phosphorylation on 
Ser2448 relative to total mTOR protein that was statistically significant after 30 min of 
hypoxia (p<0.001, n=4). Data are given as mean±SEM.. 
B) Quiescent primary RAEC were cultured for 12 h under normoxia (21% O2) and 
decreasing oxygen saturations (11%, 6%, 3%, 1% O2). Total cell lysates were 
subjected to SDS-PAGE and protein levels of mTOR, mTOR Ser2448, HIF-1α and β-
actin detected by immunoblotting.  
C) Quiescent primary RAEC were cultured for 6 h under normoxia (21% O2) (panel 
A), hypoxia (B) and hypoxia together with 20 nM rapamycin (C). Cells were fixed and 
immune-stained with anti-mTOR (FITC, green stain) and -mTOR phosphoserine 
2448 antibodies (Cy3, red stain) and nuclear compartment (DAPI; blue stain). 
Rapamycin was included during serum deprivation (24 h). 
D) Westernblot showing nuclear cell lysates of serum-deprived RAEC exposed to 
increasing periods of hypoxia (2 h to 24 h) and probed for phosphorylated Ser2448, 
HIF-1α and total mTOR.  
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Figure 2. Hypoxia increases transient or prolonged activity of distinct mTOR 
downstream targets 
A) Western blots showing total cell lysates of serum-deprived RAEC exposed to 
increasing duration of hypoxia (10 min to 24 h) and probed for (numbering from top to 
bottom) (1) phosphorylated S6K-Thr389, (2) phosphorylated S6K-Thr389 in the 
presence of 20 nM rapamycin, (3) total S6K, (4) phosphorylated Akt-Ser473, (5) total 
Akt, (6) phosphorylated Akt-Ser473 and (7) total Akt in the presence of 20 nM 
rapamycin. Nuclear extracts probed for (8) phosphorylated GSK3-Ser21/9 and (9) total 
GSK3, (10) Cyclin D1 and (11) p21.  
B) Upper graph represent ratios of S6K P-Thr389 to total S6K protein levels with and 
without rapamycin. Significant phosphorylation on S6K Thr389 occurred within 
timepoints 10min to 180 min of hypoxia (P<0.05, n=3). Lower graph represents ratios 
of Akt P-Ser473 to total Akt protein levels with and without rapamycin as calculated 
from compiled densitometric quantification. Akt Ser473 phosphorylation was significant 
after 30 min of hypoxia (P<0.01, n=3). Rapamycin treatment resulted in significant 
reduction of phosphorylation after 180 min of hypoxia (P<0.05, n=3). Data are given 
as mean±SEM. 
C) Westernblots showing total cell lysates of serum-deprived RAEC transfected with 
negative control siRNA (+si-control) or siRNA directed against mTOR (+si-mTOR) 
exposed to increasing duration of hypoxia (10 min to 24 h) and probed for 
(numbering from top to bottom) (1) total mTOR, (2) phosphorylated mTOR-Ser2448 (3) 
total Akt, (4) phosphorylated Akt-Ser473. 
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D) Graphs represent ratios of Akt P-Ser473 to total Akt protein levels as calculated 
from compiled densitometric quantification. Phosphorylation on Akt Ser473 was 
significant after 30 min of hypoxia (P<0.001, n=4). mTOR silencing significantly 
inhibited Akt P-Ser473 after 30 min of hypoxia (P<0.05, n=4). Data are given as 
mean±SEM. 
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Figure 3. mTOR and downstream targets are required for hypoxia-induced 
endothelial cell proliferation  
A) Typical micrographs (10x) of rat aortic endothelial spheroids (2000 cells) 
embedded in a fibrin gel after a 24 h incubation under normoxia (21% O2) and 
hypoxia (1% O2), normoxia (21% O2) with 20 nM rapamycin and hypoxia (1% O2) 
with 20 nM rapamycin. An additional panel shows a 40x magnification of endothelial 
sprouts emerging into the fibrin gel under hypoxia. 
B) Cell numbers of serum deprived (for 30 h) RAEC were determined after 24 h 
culturing under normoxia (21% O2) or hypoxia (1% O2) with inclusion of the indicated 
concentrations of Akt IV Inhibitor and rapamycin. Y-axis represents the mean of cell 
number, compiled from three experiments with octuplicate samples. Data are given 
as mean±SD, n=3. 
C) RAEC were nucleofected with control siRNA (si control, dark columns) and siRNA 
directed against rat mTOR (si mTOR, hatched columns). Quiescent cells were 
exposed to hypoxia for 30 hr and proliferation was measured. Significance was 
calculated by repeated ANOVA followed by pairwise comparison with the Bonferroni 
post test (ns; P>0.05, *; P<0.05, n=4). 
D) RAEC were nucleofected with control siRNA (c and dark columns) and vectors 
containing shRNA directed against raptor (rap and light columns) or rictor (ric and 
striped columns). Western blots (upper display) show efficiency of silencing and 
effects on Akt Ser473- and S6K Thr389-phosphorylation after 6 h incubation under 
hypoxia. Quiescent cells were exposed to hypoxia for 30 hr and proliferation was 
measured (lower display). Significance in was calculated by repeated ANOVA 
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followed by pairwise comparison with the Bonferroni post test ( *; P<0.05, **; 
P<0.001, n=5). 
Figure 4. Hypoxia-induced proliferation in mouse embryonic fibroblasts via 
mTOR does not depend on TSC2 and only partially on HIF-1α.  
A). Cell numbers of serum-starved TSC2 knock out (TSC2 -/-) and wild type MEF 
(upper panel) were determined after 30 h incubation under normoxia and hypoxia. 
Rapamycin or Akt inhibitor was included 30 min before incubation under hypoxia 
(upper graphs). Lower graph shows proliferation of wildtype, TSC2 mutated MEFs 
with a reintroduced TSC2 wildtype gene (TSC2mt-wt-intro) and TSC2 mutated 
(TSC2mt) MEFs as ratio of proliferation under hypoxia divided by proliferation under 
normoxia (ns; P>0.05, n=3).  
B) Cell numbers of serum-starved HIF-1α knock out (squares) and wild type MEF 
(circles) were determined after after 30 h incubation under normoxia (filled symbols) 
and hypoxia (open symbols). Rapamycin (2-200 nM) was included 30 min before 
incubation under hypoxia. Significance was calculated by one-way ANOVA followed 
by multiple comparison with the Bonferroni post test (***; P<0.001, **; P<0.01, *; 
P<0.01, n=7). 
C) HIF-1α knock out- and wild type MEFs were transfected with mock and HA-tagged 
wildtype mTOR and expression verified by westernblot (upper panel). Cell numbers 
of serum-starved mock-transfected- (dark columns) and mTOR-transfected (open 
columns) were determined after 30 h incubation under normoxia and hypoxia. The 
ratios between proliferation under normoxia and hypoxia were compared and no 
statistical difference among all groups was observed as calculated by one-way 
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ANOVA followed by multiple comparison with the Bonferroni post test (ns; P>0.05, 
n=3). 
Figure 5. Scheme representing summary of most important results.  
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Supplemental figure legend 
Cytotoxicity tests.  
RAEC were starved for 30 h and incubated for 24 h at 21% O2 and 1% O2 with 
indicated amount of Akt inhibitor IV. 100% of cytotoxicity was determined by cell lysis 
with 2% Triton X-100. Akt inhibitor IV concentrations used for proliferation assays are 
indicated and range in nontoxic doses. Cytotoxicity was measured with the Roche 
celltoxicity kit (Roche Molecular Biochemicals, Rotkreuz, Switzerland) according to 
the manufacturer’s specifications. 
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
CIRCRESAHA/2006/140095-R2 
 28
ACKNOWLEDGMENTS 
This work was supported by grants from the Swiss National Science Foundation 
(3200-067155), the Swiss Cancer League (OCS 01160-09-2001) and the Swiss 
Heart Foundation. We thank Max Gassmann (Institute for Veterinary Physiology, 
University Zurich, Switzerland) for providing material. Furthermore we thank Kaija 
Paris (University Hospital Basel, Switzerland) for technical assistance. 
 
CONFLICT(S) OF INTEREST 
none 
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
CIRCRESAHA/2006/140095-R2 
 29
REFERENCES 
 
1. Giaccia AJ, Simon MC, Johnson R. The biology of hypoxia: the role of oxygen 
sensing in development, normal function, and disease. Genes Dev. 
2004;18:2183-94. 
2. Ten VS, Pinsky DJ. Endothelial response to hypoxia: physiologic adaptation 
and pathologic dysfunction. Curr Opin Crit Care. 2002;8:242-50. 
3. Tretyakov AV, Farber HW. Endothelial cell tolerance to hypoxia. Potential role 
of purine nucleotide phosphates. J Clin Invest. 1995;95:738-44. 
4. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF 
system. Nat Med. 2003;9:677-84. 
5. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances 
vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-
dependent signaling. Faseb J. 2002;16:771-80. 
6. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. 
Curr Opin Cell Biol. 2005;17:596-603. 
7. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. 
Cell. 2006;124:471-84. 
8. Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell 
Biol. 2005;17:158-66. 
9. Yonezawa K, Yoshino KI, Tokunaga C, Hara K. Kinase activities associated 
with mTOR. Curr Top Microbiol Immunol. 2004;279:271-82. 
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
CIRCRESAHA/2006/140095-R2 
 30
10. Yonezawa K, Tokunaga C, Oshiro N, Yoshino K. Raptor, a binding partner of 
target of rapamycin. Biochem Biophys Res Commun. 2004;313:437-41. 
11. Oshiro N, Yoshino K, Hidayat S, Tokunaga C, Hara K, Eguchi S, Avruch J, 
Yonezawa K. Dissociation of raptor from mTOR is a mechanism of rapamycin-
induced inhibition of mTOR function. Genes Cells. 2004;9:359-66. 
12. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, 
Tempst P, Sabatini DM. mTOR interacts with raptor to form a nutrient-
sensitive complex that signals to the cell growth machinery. Cell. 
2002;110:163-75. 
13. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, 
Oppliger W, Jenoe P, Hall MN. Two TOR complexes, only one of which is 
rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 
2002;10:457-68. 
14. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN. 
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin 
insensitive. Nat Cell Biol. 2004;6:1122-8. 
15. Sarbassov dos D, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage 
H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a 
rapamycin-insensitive and raptor-independent pathway that regulates the 
cytoskeleton. Curr Biol. 2004;14:1296-302. 
16. Hresko RC, Mueckler M. mTOR/RICTOR is the Ser473 kinase for Akt/PKB in 
3T3-L1 adipocytes. J Biol Chem. 2005. 
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
CIRCRESAHA/2006/140095-R2 
 31
17. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098-
101. 
18. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 
2005;8:179-83. 
19. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, 
Cordon-Cardo C, Simon MC, Rafii S, Pandolfi PP. PML inhibits HIF-1alpha 
translation and neoangiogenesis through repression of mTOR. Nature. 
2006;442:779-85. 
20. Gerasimovskaya EV, Tucker DA, Stenmark KR. Activation of 
Phosphatidylinositol 3-Kinase, Akt and Mammalian Target of Rapamycin 
(mTOR) Is Necessary for Hypoxia-Induced Pulmonary Artery Adventitial 
Fibroblast Proliferation. J Appl Physiol. 2004. 
21. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia 
AJ, Abraham RT. Regulation of hypoxia-inducible factor 1alpha expression 
and function by the mammalian target of rapamycin. Mol Cell Biol. 
2002;22:7004-14. 
22. Connolly E, Braunstein S, Formenti S, Schneider RJ. Hypoxia inhibits protein 
synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled 
by mTOR and uncoupled in breast cancer cells. Mol Cell Biol. 2006;26:3955-
65. 
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
CIRCRESAHA/2006/140095-R2 
 32
23. Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-
independent hypoxic response regulating mammalian target of rapamycin and 
its targets. J Biol Chem. 2003;278:29655-60. 
24. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, 
Ellisen LW, Kaelin WG, Jr. Regulation of mTOR function in response to 
hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes 
Dev. 2004;18:2893-904. 
25. Korff T, Kimmina S, Martiny-Baron G, Augustin HG. Blood vessel maturation in 
a 3-dimensional spheroidal coculture model: direct contact with smooth 
muscle cells regulates endothelial cell quiescence and abrogates VEGF 
responsiveness. Faseb J. 2001;15:447-57. 
26. Blindenbacher A, Wang X, Langer I, Savino R, Terracciano L, Heim MH. 
Interleukin 6 is important for survival after partial hepatectomy in mice. 
Hepatology. 2003;38:674-82. 
27. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates 
endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J 
Cell Biol. 1994;125:917-28. 
28. Roy S, Khanna S, Bickerstaff AA, Subramanian SV, Atalay M, Bierl M, 
Pendyala S, Levy D, Sharma N, Venojarvi M, Strauch A, Orosz CG, Sen CK. 
Oxygen sensing by primary cardiac fibroblasts: a key role of 
p21(Waf1/Cip1/Sdi1). Circ Res. 2003;92:264-71. 
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
CIRCRESAHA/2006/140095-R2 
 33
29. Kim JE, Chen J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-
associated protein is involved in rapamycin-sensitive signaling and translation 
initiation. Proc Natl Acad Sci U S A. 2000;97:14340-5. 
30. von Manteuffel SR, Dennis PB, Pullen N, Gingras AC, Sonenberg N, Thomas 
G. The insulin-induced signalling pathway leading to S6 and initiation factor 4E 
binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point 
immediately upstream of p70s6k. Mol Cell Biol. 1997;17:5426-36. 
31. Pearson RB, Dennis PB, Han JW, Williamson NA, Kozma SC, Wettenhall RE, 
Thomas G. The principal target of rapamycin-induced p70s6k inactivation is a 
novel phosphorylation site within a conserved hydrophobic domain. Embo J. 
1995;14:5279-87. 
32. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of 
glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 
1995;378:785-9. 
33. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its 
discovery. Biochem J. 2001;359:1-16. 
34. Li Y, Corradetti MN, Inoki K, Guan KL. TSC2: filling the GAP in the mTOR 
signaling pathway. Trends Biochem Sci. 2004;29:32-8. 
35. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by 
Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648-57. 
36. Mazure NM, Brahimi-Horn MC, Berta MA, Benizri E, Bilton RL, Dayan F, 
Ginouves A, Berra E, Pouyssegur J. HIF-1: master and commander of the 
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
CIRCRESAHA/2006/140095-R2 
 34
hypoxic world. A pharmacological approach to its regulation by siRNAs. 
Biochem Pharmacol. 2004;68:971-80. 
37. Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. 
Curr Opin Genet Dev. 1998;8:588-94. 
38. Abraham RT. mTOR as a positive regulator of tumor cell responses to 
hypoxia. Curr Top Microbiol Immunol. 2004;279:299-319. 
39. Sarbassov dos D, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, 
Markhard AL, Sabatini DM. Prolonged Rapamycin Treatment Inhibits 
mTORC2 Assembly and Akt/PKB. Mol Cell. 2006;22:159-68. 
40. Schumacker PT. Hypoxia, anoxia, and O2 sensing: the search continues. Am 
J Physiol Lung Cell Mol Physiol. 2002;283:L918-21. 
41. Holz MK, Blenis J. Identification of S6 kinase 1 as a novel mammalian target 
of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem. 2005;280:26089-
93. 
42. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi 
PP. Identification of a tumour suppressor network opposing nuclear Akt 
function. Nature. 2006;441:523-7. 
43. Sarbassov DD, Sabatini DM. Redox regulation of the nutrient-sensitive raptor-
mTOR pathway and complex. J Biol Chem. 2005. 
44. Dames SA, Mulet JM, Rathgeb-Szabo K, Hall MN, Grzesiek S. The solution 
structure of the FATC domain of the protein kinase target of rapamycin 
suggests a role for redox-dependent structural and cellular stability. J Biol 
Chem. 2005;280:20558-64. 
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
CIRCRESAHA/2006/140095-R2 
 35
45. Schieke SM, Phillips D, McCoy JP, Jr., Aponte AM, Shen RF, Balaban RS, 
Finkel T. The mTOR pathway regulates mitochondrial oxygen consumption 
and oxidative capacity. J Biol Chem. 2006. 
46. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, Ferrara N, 
Johnson RS. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven 
VEGF autocrine loop necessary for tumorigenesis. Cancer Cell. 2004;6:485-
95. 
 
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
 Circulation Research Manuscript #CIRCRESAHA/2006/140095 - R2 Original Contribution
